129 related articles for article (PubMed ID: 38849938)
41. Visualization and quantification of
Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
[TBL] [Abstract][Full Text] [Related]
42. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.
Nalawade SA; Shafer P; Bajgain P; McKenna MK; Ali A; Kelly L; Joubert J; Gottschalk S; Watanabe N; Leen A; Parihar R; Vera Valdes JF; Hoyos V
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815355
[TBL] [Abstract][Full Text] [Related]
43. Gemcitabine chemotherapy induces phenotypic alterations of tumor cells that facilitate antitumor T cell responses in a mouse model of oral cancer.
Tomihara K; Fuse H; Heshiki W; Takei R; Zhang B; Arai N; Nakamori K; Noguchi M
Oral Oncol; 2014 May; 50(5):457-67. PubMed ID: 24582211
[TBL] [Abstract][Full Text] [Related]
44. Co-delivery of docetaxel and gemcitabine by anacardic acid modified self-assembled albumin nanoparticles for effective breast cancer management.
Kushwah V; Katiyar SS; Dora CP; Kumar Agrawal A; Lamprou DA; Gupta RC; Jain S
Acta Biomater; 2018 Jun; 73():424-436. PubMed ID: 29649635
[TBL] [Abstract][Full Text] [Related]
45. Her2-Targeted Multifunctional Nano-Theranostic Platform Mediates Tumor Microenvironment Remodeling and Immune Activation for Breast Cancer Treatment.
Zheng D; Wan C; Yang H; Xu L; Dong Q; Du C; Du J; Li F
Int J Nanomedicine; 2020; 15():10007-10028. PubMed ID: 33376321
[TBL] [Abstract][Full Text] [Related]
46. Sequential depletion of myeloid-derived suppressor cells and tumor cells with a dual-pH-sensitive conjugated micelle system for cancer chemoimmunotherapy.
Wan D; Yang Y; Liu Y; Cun X; Li M; Xu S; Zhao W; Xiang Y; Qiu Y; Yu Q; Tang X; Zhang Z; He Q
J Control Release; 2020 Jan; 317():43-56. PubMed ID: 31758970
[TBL] [Abstract][Full Text] [Related]
47. Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response.
Dammeijer F; De Gooijer CJ; van Gulijk M; Lukkes M; Klaase L; Lievense LA; Waasdorp C; Jebbink M; Bootsma GP; Stigt JA; Biesma B; Kaijen-Lambers MEH; Mankor J; Vroman H; Cornelissen R; Baas P; Van der Noort V; Burgers JA; Aerts JG
EBioMedicine; 2021 Feb; 64():103160. PubMed ID: 33516644
[TBL] [Abstract][Full Text] [Related]
48. Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib.
Yin N; Yu H; Zhang X; Lv X
Drug Des Devel Ther; 2020; 14():4465-4475. PubMed ID: 33122890
[TBL] [Abstract][Full Text] [Related]
49. Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer.
Zhao X; Li F; Li Y; Wang H; Ren H; Chen J; Nie G; Hao J
Biomaterials; 2015 Apr; 46():13-25. PubMed ID: 25678112
[TBL] [Abstract][Full Text] [Related]
50. Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways.
Sawant A; Schafer CC; Jin TH; Zmijewski J; Tse HM; Roth J; Sun Z; Siegal GP; Thannickal VJ; Grant SC; Ponnazhagan S; Deshane JS
Cancer Res; 2013 Nov; 73(22):6609-20. PubMed ID: 24085788
[TBL] [Abstract][Full Text] [Related]
51. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
[TBL] [Abstract][Full Text] [Related]
52. (-)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer.
Lin H; Wu Y; Chen J; Huang S; Wang Y
Pharm Res; 2018 Jul; 35(9):183. PubMed ID: 30062658
[TBL] [Abstract][Full Text] [Related]
53. Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells.
Zhang X; Taoka R; Liu D; Matsuoka Y; Tohi Y; Kakehi Y; Sugimoto M
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921102
[TBL] [Abstract][Full Text] [Related]
54. Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects.
Suzuki E; Sun J; Kapoor V; Jassar AS; Albelda SM
Cancer Biol Ther; 2007 Jun; 6(6):880-5. PubMed ID: 17582217
[TBL] [Abstract][Full Text] [Related]
55. Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis.
Ho TTB; Nasti A; Seki A; Komura T; Inui H; Kozaka T; Kitamura Y; Shiba K; Yamashita T; Yamashita T; Mizukoshi E; Kawaguchi K; Wada T; Honda M; Kaneko S; Sakai Y
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33188035
[TBL] [Abstract][Full Text] [Related]
56. Role of myeloid-derived suppressor cells in tumor immunotherapy.
Martin F; Apetoh L; Ghiringhelli F
Immunotherapy; 2012 Jan; 4(1):43-57. PubMed ID: 22150000
[TBL] [Abstract][Full Text] [Related]
57. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo.
Tongu M; Harashima N; Monma H; Inao T; Yamada T; Kawauchi H; Harada M
Cancer Immunol Immunother; 2013 Feb; 62(2):383-91. PubMed ID: 22926062
[TBL] [Abstract][Full Text] [Related]
58. Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity.
Sangaletti S; Tripodo C; Santangelo A; Castioni N; Portararo P; Gulino A; Botti L; Parenza M; Cappetti B; Orlandi R; Tagliabue E; Chiodoni C; Colombo MP
Cell Rep; 2016 Sep; 17(1):233-248. PubMed ID: 27681434
[TBL] [Abstract][Full Text] [Related]
59. Maitake α-glucan promotes differentiation of monocytic myeloid-derived suppressor cells into M1 macrophages.
Masuda Y; Nakayama Y; Shimizu R; Naito K; Miyamoto E; Tanaka A; Konishi M
Life Sci; 2023 Mar; 317():121453. PubMed ID: 36709912
[TBL] [Abstract][Full Text] [Related]
60. RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells.
Soong RS; Anchoori RK; Yang B; Yang A; Tseng SH; He L; Tsai YC; Roden RB; Hung CF
Oncotarget; 2016 Oct; 7(42):68489-68502. PubMed ID: 27655678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
